Is angiogenesis inhibition the Holy Grail of cancer therapy?

Current Opinion in Oncology

Volumn 12, Issue 1, 2000, Pages 89-94

  Boehm Viswanathan, Thomas ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; EPHRIN; EPHRIN RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

CANCER; CANCER GROWTH; DRUG EFFICACY; HUMAN; HYPOXIA; PRIORITY JOURNAL; REVIEW; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANOXIA; CELL TRANSFORMATION, NEOPLASTIC; ENDOTHELIAL GROWTH FACTORS; HUMANS; LYMPHOKINES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034519201     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200001000-00015     Document Type: Review

References (27)

1. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors
2. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
3. A new role for hypoxia in tumor progression: Induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs
4. The molecular basis of the hypoxia response pathway: Tumour hypoxia as a therapy target
5. Hypoxia-induced up-regulation of angiogenin in human malignant melanoma
6. Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development
7. Structure, expression and receptor-binding properties of novel vascular endothelial growth factors
8. Vascular endothelial growth factor (VEGF) and its receptors
9. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
10. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
11. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
12. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development
13. Vessel cooption, regression, and growth in tumors mediated by angiogoietins and VEGF
14. Biologic significance of angiopoetin-2 expression in human hepatocellular carcinoma
15. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2
16. Two independent mechanisms essential for tumor angiogenesis: Inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway
17. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells
18. Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF- α-induced angiogenesis
19. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4
20. Roles of ephrinB ligands and EphB receptors in cardiovascular development: Demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogensis
21. Eph receptors and ephrins restrict cell intermingling and communication
22. Chemotherapy targetec to tumor vasculature
23. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display
24. NG2 proteoglycan-binding peptides target tumor neovasculature
25. Why angiogenesis inhibition?
26. Molecular angiogenesis
27. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis